Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹43.16 Cr |
| Reserved for Market Maker | ₹0.00 Cr |
| Net Issue Size | ₹43.16 Cr |
| Fresh Issue | ₹40.95 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹93.00-97.00 per share |
| Discount | Retail: 0.00 |
| NSE Code | QUESTLAB |
| Registrar | Bigshare Services Pvt.Ltd. |
| Lead Managers | Shreni Shares Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 1,200 shares and in multiples thereof
Incorporated in June 1998, Quest Laboratories Limited is a pharmaceutical company manufacturing a range of antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more.
The company operates in the domestic market across twelve (12) states and two (2) union territories. These include Uttar Pradesh, Madhya Pradesh, Maharashtra, Delhi, Jharkhand, Assam, Karnataka, Jammu & Kashmir, Rajasthan, West Bengal, Gujarat, Telangana, Haryana, and Bihar.
The manufacturing unit of the company is located in Dhar, Madhya Pradesh.
The company holds WHO Schedule M GMP and GLP certifications, as well as ISO/IEC 17025:2017 and ISO 9001:2015 certifications.
By December 31st, 2023, the company employs 83 individuals to lookafter various aspects of its manufacturing operations, including production, quality control, technical and engineering support services, inventory management, administration, accounting, and other functions such as storage, packing, and dispatch.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility | 26.00 |
| 2 | Funding Working Capital Requirements of the Company | 10.00 |
| 3 | General corporate purposes | 3.38 |
| Period Ended | 31 Dec 2023 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Assets | 58.69 | 46.65 | 34.80 | 18.40 |
| Total Income | 62.18 | 61.87 | 59.54 | 30.44 |
| Profit After Tax | 7.75 | 5.03 | 4.11 | 0.66 |
| NET Worth | 22.77 | 15.02 | 9.99 | 5.89 |
| Reserves and Surplus | 11.98 | 13.94 | 8.92 | 4.81 |
| Total Borrowing | 4.61 | 4.10 | 3.13 | 3.04 |
| Amount in ₹ Crore | ||||
| KPI | Dec 31, 2023 |
|---|---|
| ROE | 34.03% |
| ROCE | 41.86% |
| Debt / Equity | 0.20% |
| RoNW | 34.03% |
| PAT Margin | 12.48% |
| Price to Book Value | 4.59 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 4.21 | 6.31 |
| P/E (x) | 23.03 | 15.38 |
| Promoter Holding | 90.36% | 65.82% |
| Market Cap | ₹158.96 Cr. | |
